Scarica l'app Stockscreener
1.72
4.24%
0.07
Dopo l'orario di chiusura:
1.70
-0.02
-1.16%
Precedente Chiudi:
$1.65
Aprire:
$1.68
Volume 24 ore:
50,649
Relative Volume:
0.47
Capitalizzazione di mercato:
$21.50M
Reddito:
$10.16M
Utile/perdita netta:
$-47.57M
Rapporto P/E:
-0.2087
EPS:
-8.24
Flusso di cassa netto:
$-42.73M
1 W Prestazione:
+2.99%
1M Prestazione:
-6.01%
6M Prestazione:
-45.22%
1 anno Prestazione:
-61.17%
Intervallo 1D:
$1.67
$1.7899
Intervallo di 1 settimana:
$1.62
$1.7899
Portata 52W:
$1.02
$8.29
Curis Inc Stock (CRIS) Company Profile
Nome
Curis Inc
Settore
Industria
Telefono
617-503-6500
Indirizzo
128 SPRING STREET, LEXINGTON, MA
Confronta CRIS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
1.72 | 19.80M | 10.16M | -47.57M | -42.73M | -8.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-19 | Ripresa | H.C. Wainwright | Buy |
| 2023-11-17 | Iniziato | Truist | Buy |
| 2022-04-04 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-10-13 | Iniziato | Raymond James | Outperform |
| 2021-03-25 | Iniziato | B. Riley Securities | Buy |
| 2020-07-29 | Iniziato | Laidlaw | Buy |
| 2020-07-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2016-03-02 | Iniziato | Sun Trust Rbsn Humphrey | Buy |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-08-11 | Iniziato | FBR Capital | Outperform |
| 2015-01-22 | Reiterato | Oppenheimer | Outperform |
| 2015-01-21 | Reiterato | ROTH Capital | Buy |
| 2014-05-09 | Reiterato | Oppenheimer | Outperform |
| 2013-10-02 | Iniziato | Robert W. Baird | Outperform |
| 2013-09-30 | Iniziato | Chardan Capital Markets | Buy |
| 2012-11-14 | Iniziato | Stifel Nicolaus | Hold |
| 2012-01-31 | Reiterato | Brean Murray | Buy |
| 2012-01-31 | Reiterato | Summer Street Research | Buy |
| 2011-12-09 | Iniziato | Oppenheimer | Outperform |
| 2011-10-06 | Iniziato | Summer Street Research | Buy |
| 2011-09-22 | Iniziato | MLV Capital | Buy |
| 2011-03-21 | Reiterato | Brean Murray | Buy |
| 2010-02-26 | Reiterato | Roth Capital | Buy |
| 2010-01-07 | Iniziato | Roth Capital | Buy |
Mostra tutto
Curis Inc Borsa (CRIS) Ultime notizie
Market reaction to Curis Inc.’s recent newsAsset Safety Selection Using Quantitative Analysis - Newser
Exit strategy if you’re trapped in Curis Inc.Next Day Momentum Stock Forecasting Report - Newser
What makes Curis Inc. stock price move sharplyGiant Leap Stock Alerts - thegnnews.com
Curis Inc. Receives Buy Rating Due to Promising Clinical Developments and Strong Financial Position. - AInvest
Curis Files Prospectus Supplement for Stock Offering - MSN
Curis Inc. Receives Buy Rating Amid Promising Clinical Developments and Strong Financial Position - TipRanks
Curis targets enrolling 30–40 additional patients for NDA and EMA submissions as emavusertib studies advance - MSN
Curis, Inc. (NASDAQ:CRIS) Just Reported, And Analysts Assigned A US$16.33 Price Target - simplywall.st
Curis, Inc. Analysts Trim Price Target After Q2 Report - AInvest
Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates - MSN
Curis, Inc. Reports Q2 2025 Financial and Clinical Progress - The Globe and Mail
Curis 2025 Q2 Earnings Narrowed Losses Amid Strong Revenue Growth - AInvest
Curis, Inc. shares rise 1.74% intraday as Swiss president meets business leaders in Washington ahead of tariff talks. - AInvest
Curis Inc (CRIS) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Curis, Inc. (NASDAQ:CRIS) Q2 2025 Earnings Call Transcript - Insider Monkey
Curis Provides Second Quarter 2025 Business Update - BioSpace
Curis: Q2 Earnings Snapshot - New Haven Register
Curis Inc. Earnings Call: Progress Amid Challenges - TipRanks
Curis Inc. Q2 Earnings Call Highlights: Progress Amid Challenges - AInvest
Curis (CRIS) Q2 Loss Narrows 66% - The Motley Fool
Curis Inc: Promising Financial Performance and Clinical Advancements Justify Buy Rating - TipRanks
Earnings call transcript: Curis Inc’s Q2 2025 sees reduced losses, stock rises - Investing.com
Earnings call transcript: Curis Inc’s Q2 2025 sees reduced losses, stock rises By Investing.com - Investing.com South Africa
Curis Inc: A High-Conviction Biotech Play with Accelerating Catalysts in Hematology - AInvest
Curis, Inc. Q2 2025: Unraveling Contradictions in Enrollment Strategy, FDA Dynamics, and PCNSL Data Expectations - AInvest
Transcript : Curis, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Curis Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Biotech firm Curis Q2 revenue rises to $2.7 mln - MarketScreener
Curis Inc (CRIS) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
How strong is Curis Inc. company’s balance sheetTrack top-performing stocks effortlessly - Jammu Links News
What are the technical indicators suggesting about Curis Inc.Exceptional gains - Jammu Links News
Curis Inc Q2 2025 Earnings Report Preview: Revenue Expected to Reach $2.64 Million, Earnings at -$1.36 per Share - AInvest
What catalysts could drive Curis Inc. stock higher in 2025Achieve breakthrough investment performance - Jammu Links News
How does Curis Inc. compare to its industry peersGet real-time updates on market trends - Jammu Links News
What drives Curis Inc. stock priceUnmatched market gains - Jammu Links News
What are Curis Inc. company’s key revenue driversInvest smarter with daily trading signals - Jammu Links News
What are analysts’ price targets for Curis Inc. in the next 12 monthsTurn volatility into profit opportunities - Jammu Links News
What is Curis Inc. company’s growth strategyBreakthrough financial growth - Jammu Links News
Is it the right time to buy Curis Inc. stockPhenomenal trading returns - Jammu Links News
Can machine learning forecast Curis Inc. recoverySmart Stock Forecast Using AI Algorithms - newser.com
Is Curis Inc. a growth stock or a value stockExtraordinary profit generation - Jammu Links News
What institutional investors are buying Curis Inc. stockMaximize your returns with expert insights - Jammu Links News
When is Curis Inc. stock expected to show significant growthHigh-margin investment plays - Jammu Links News
Curis Inc Azioni (CRIS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):